GPAC launches Spanish version of NAPOS drug safety database for porphyria

By AI, Created 4:41 PM UTC, May 18, 2026, /AGP/ – The Global Porphyria Advocacy Coalition has launched a Spanish-language version of the NAPOS Safe Drugs Database on Global Porphyria Day to improve medication safety for people with acute porphyrias. The tool is designed to help clinicians and patients quickly identify medicines that are safe, unsafe or require specialist supervision.

Why it matters: - The Spanish launch aims to reduce language barriers that can delay access to critical drug-safety information for Spanish-speaking clinicians and patients. - Acute porphyria patients can face severe, potentially life-threatening attacks if they receive certain commonly prescribed medications. - Faster access to medication risk classifications can improve patient safety in primary care, emergency settings, hospital care and multidisciplinary treatment.

What happened: - The Global Porphyria Advocacy Coalition announced the official Spanish-language launch of the NAPOS Safe Drugs Database on May 18, Global Porphyria Day. - The database is a clinical reference for the acute hepatic porphyrias and was developed by the Norwegian Porphyria Centre, known as NAPOS. - The tool is now available for Spanish-speaking healthcare professionals and patients.

The details: - The database provides guidance on medicines considered safe, unsafe or requiring specialist supervision. - The resource covers Acute Intermittent Porphyria, Variegate Porphyria, Hereditary Coproporphyria and ALA Dehydratase Deficiency Porphyria. - Clinicians and specialists use the database as a technical reference for therapeutic decisions. - NAPOS manages the database in collaboration with the International Porphyria Network, the Safety of Drugs for Porphyria Patients Working Group and the UK Porphyria Medicines Information Service. - Assessments are based on international clinical experience, published case reports and pharmacological data. - GPAC said the initiative was supported by an educational grant from Alnylam Pharmaceuticals to expand global access to drug-safety information for porphyria patients. - GPAC also credited translation leadership from Dr. Magne Rekdal and the NAPOS team, plus medical review by Dr. Isaac Hindi. - GPAC shared its social channels, Instagram, Facebook, YouTube and X.

Between the lines: - The launch is not just a translation project. It is an access issue for a rare-disease community that depends on fast medication decisions. - GPAC framed language accessibility as part of patient safety, especially in urgent care situations where porphyria-specific drug risk can be easy to miss. - The project also shows how patient groups, clinical networks and industry funding can combine to expand access to specialist medical information.

What’s next: - The Spanish version is expected to help physicians, emergency teams and primary care professionals make more confident decisions in critical situations. - GPAC is positioning the database as a tool to improve safety and reduce inequities for Spanish-speaking communities living with porphyria. - Broader use of the resource could strengthen patient education and family awareness alongside clinical care.

The bottom line: - The Spanish-language NAPOS database gives clinicians and patients a clearer way to check porphyria-related drug risk when minutes matter.